These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32818158)

  • 1. Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders.
    Savardi A; Borgogno M; Narducci R; La Sala G; Ortega JA; Summa M; Armirotti A; Bertorelli R; Contestabile A; De Vivo M; Cancedda L
    Chem; 2020 Aug; 6(8):2073-2096. PubMed ID: 32818158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Development of the Na-K-2Cl Co-transporter-1 (NKCC1) Inhibitor ARN23746 for the Treatment of Neurodevelopmental Disorders.
    Savardi A; Patricelli Malizia A; De Vivo M; Cancedda L; Borgogno M
    ACS Pharmacol Transl Sci; 2023 Jan; 6(1):1-11. PubMed ID: 36654749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis,
    Borgogno M; Savardi A; Manigrasso J; Turci A; Portioli C; Ottonello G; Bertozzi SM; Armirotti A; Contestabile A; Cancedda L; De Vivo M
    J Med Chem; 2021 Jul; 64(14):10203-10229. PubMed ID: 34137257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNS pharmacology of NKCC1 inhibitors.
    Löscher W; Kaila K
    Neuropharmacology; 2022 Mar; 205():108910. PubMed ID: 34883135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological tools to target NKCC1 in brain disorders.
    Savardi A; Borgogno M; De Vivo M; Cancedda L
    Trends Pharmacol Sci; 2021 Dec; 42(12):1009-1034. PubMed ID: 34620512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-Label Use of Bumetanide for Brain Disorders: An Overview.
    Kharod SC; Kang SK; Kadam SD
    Front Neurosci; 2019; 13():310. PubMed ID: 31068771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of bumetanide as a potential therapeutic agent for Alzheimer's disease.
    Boyarko B; Podvin S; Greenberg B; Momper JD; Huang Y; Gerwick WH; Bang AG; Quinti L; Griciuc A; Kim DY; Tanzi RE; Feldman HH; Hook V
    Front Pharmacol; 2023; 14():1190402. PubMed ID: 37601062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex.
    Conti L; Palma E; Roseti C; Lauro C; Cipriani R; de Groot M; Aronica E; Limatola C
    Epilepsia; 2011 Sep; 52(9):1635-44. PubMed ID: 21635237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
    Brandt C; Seja P; Töllner K; Römermann K; Hampel P; Kalesse M; Kipper A; Feit PW; Lykke K; Toft-Bertelsen TL; Paavilainen P; Spoljaric I; Puskarjov M; MacAulay N; Kaila K; Löscher W
    Neuropharmacology; 2018 Dec; 143():186-204. PubMed ID: 30248303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rat NKCC2/NKCC1 cotransporter selectivity for loop diuretic drugs.
    Hannaert P; Alvarez-Guerra M; Pirot D; Nazaret C; Garay RP
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):193-9. PubMed ID: 11882915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A.
    Lykke K; Töllner K; Feit PW; Erker T; MacAulay N; Löscher W
    Epilepsy Behav; 2016 Jun; 59():42-9. PubMed ID: 27088517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases.
    Jaggi AS; Kaur A; Bali A; Singh N
    Curr Neuropharmacol; 2015; 13(3):369-88. PubMed ID: 26411965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKCC1 Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders.
    Ben-Ari Y
    Trends Neurosci; 2017 Sep; 40(9):536-554. PubMed ID: 28818303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chloride co-transporters, NKCC1 and KCC2, in experimental autoimmune encephalomyelitis (EAE).
    Yousuf MS; Zubkow K; Tenorio G; Kerr B
    Neuroscience; 2017 Mar; 344():178-186. PubMed ID: 28057537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Alteration of Chloride Homeostasis/GABAergic Signaling in Brain Disorders: Could Oxidative Stress Play a Role?
    Abruzzo PM; Panisi C; Marini M
    Antioxidants (Basel); 2021 Aug; 10(8):. PubMed ID: 34439564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures.
    Kahle KT; Staley KJ
    Neurosurg Focus; 2008 Sep; 25(3):E22. PubMed ID: 18759624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of NKCC1 and KCC2 in Epilepsy: From Expression to Function.
    Liu R; Wang J; Liang S; Zhang G; Yang X
    Front Neurol; 2019; 10():1407. PubMed ID: 32010056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Na
    Zhang J; Pu H; Zhang H; Wei Z; Jiang X; Xu M; Zhang L; Zhang W; Liu J; Meng H; Stetler RA; Sun D; Chen J; Gao Y; Chen L
    Neurochem Int; 2017 Dec; 111():23-31. PubMed ID: 28577991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of NKCC1 phosphorylation avoids downregulation of KCC2 in central sensory pathways and reduces neuropathic pain after peripheral nerve injury.
    Mòdol L; Cobianchi S; Navarro X
    Pain; 2014 Aug; 155(8):1577-1590. PubMed ID: 24813295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Slc12a1 expression in β-cells and improved glucose disposal in Slc12a2 heterozygous mice.
    Alshahrani S; Almutairi MM; Kursan S; Dias-Junior E; Almiahuob MM; Aguilar-Bryan L; Di Fulvio M
    J Endocrinol; 2015 Dec; 227(3):153-65. PubMed ID: 26400961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.